Clarus Biologics, Inc.
Developer of a virus-like particle (VLP) vaccine/adjuvant platform intended to enhance immune activation, elicit mucosal and systemic antibody and T-cell responses, enable antigen-sparing, and support rapid deployment strategies. The company reports extensive pre-clinical testing across multiple species (including non-human primates), seeks cGMP clinical-grade production, and pursues licensing and commercialization pathways.
Industries
N/A
Products
VLP-based vaccine adjuvant platform
A virus-like particle platform intended to be mixed with pathogen-specific antigens to increase innate activation and enhance antibody, T-cell and mucosal responses while enabling antigen dose reduction; reported extensive pre-clinical data including protection in challenge models.
VLP-based vaccine adjuvant platform
A virus-like particle platform intended to be mixed with pathogen-specific antigens to increase innate activation and enhance antibody, T-cell and mucosal responses while enabling antigen dose reduction; reported extensive pre-clinical data including protection in challenge models.
Expertise Areas
- Vaccine adjuvant development
- Pre-clinical vaccine evaluation
- Immunology and mucosal immunity
- Biologics platform development
Key Technologies
- Virus-like particles (VLP)
- Alphavirus-derived RNA platforms
- Mucosal immunity induction
- Antigen-sparing adjuvant approaches